Network Insights Methodology Whitepaper Get Access

Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 7.8ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$62B market cap (Copenhagen-listed) Novo Nordisk manufactures insulin, GLP-1 agonists (Ozempic, Wegovy), and specialty care drugs. Late-stage cardiovascular inflammation drug failed primary endpoint in Phase III trial, triggering stock decline and portfolio reassessment.

No active M&A or investment activity reported. Clinical trial failure in cardiovascular drug program may impact pipeline valuation and R&D strategy.
0.74
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
7.8
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
29
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novo Nordisk is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
Eli Lilly FDA China PlocamiumAI United States India Canada Merck Wall Street New Jersey OpenAI AstraZeneca CEO Bloomberg Americans
Watch This Entity
PSI Intelligence
30-Day Trend
2026-08-03 2026-08-15 30 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
437.519
Sentiment-Momentum Divergence
0.000
Source Concentration
0.321
Signal
Novo Nordisk is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #4 of 73 in Health Care — above 96% of sector peers. PSI down 0.21 from yesterday (0.56 -> 0.35).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
4 of 73
Sector Rank
+1.20
Peer Z-Score
96%
Sector Percentile
Network Analysis
29 Degree Centrality
Ego Network (top connections)
Eli Lilly (weight 39.0)FDA (weight 31.0)China (weight 19.0)PlocamiumAI (weight 13.0)United States (weight 10.0)India (weight 8.0)Canada (weight 6.0)Merck (weight 6.0) Eli LillyFDAChinaPlocamiumAIUnited StatesIndiaCanadaMerck Novo Nordisk (degree 29) Novo Nordisk
Centrality History
2026-08-03 2026-08-15 30 0 Degree Mentions
EntityWeight StatusFirst Seen
Eli Lilly 39 NEW
FDA 31 NEW
China 19 NEW
PlocamiumAI 13 NEW
United States 10 NEW
India 8 NEW
Canada 6 NEW
Merck 6 NEW
Wall Street 5 NEW
New Jersey 4 NEW
OpenAI 4 NEW
AstraZeneca 4 NEW
CEO 3 NEW
Bloomberg 3 NEW
Americans 3 NEW
AWS 3 NEW
Amazon Web Services 3 NEW
London 3 NEW
Amazon 3 NEW
European Union 3 NEW
Reuters 3 NEW
Asia 2 NEW
Samsung 2 NEW
DOD 2 NEW
Senate 2 NEW
Anthropic 2 NEW
United Kingdom 2 NEW
Netflix 2 NEW
Investing.com 2 NEW
Article Coverage (2)
DateLaneTitle
2026-08-12 Healthcare Marketing Lilly Escalates Patent Fight Over Retatrutide as Knockoff Sales Threaten Profit
2026-08-11 Healthcare M&A Judge Blocks Pentagon's China Military Label on WuXi AppTec, Reshaping Biotech Supply Chain

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-08-15 ← Intelligence Network